Physician profile
Kellen M Rolling
NPI 1821310095
$11,272.36
in general payments reported to CMS, 2019-2025
38 companies · $1,543 in 2025
The $1,543 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,928 · 2022: $2,825 · 2023: $2,349 · 2024: $1,628 · 2025: $1,543.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,519.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,519.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,834.68 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $2,236.28 | 2021-2025 | |
| Lilly USA, LLC | $1,295.50 | 2021-2025 | Zepbound, Mounjaro, Jardiance |
| Amgen INC. | $738.42 | 2021-2025 | Repatha, Otezla, Evenity |
| Takeda Pharmaceuticals U.S.A., INC. | $649.18 | 2021-2025 | Trintellix |
| Pfizer INC. | $354.56 | 2021-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $278.77 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $252.15 | 2021-2022 | |
| Ibsa Pharma INC. | $229.39 | 2021-2024 | Tirosint, Tirosint, Licart |
| Amarin Pharma, INC. | $199.94 | 2021-2023 | |
| Dexcom, INC. | $192.58 | 2021-2025 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $192.32 | 2023-2025 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $186.91 | 2021-2025 | Airsupra |
| Eisai INC. | $143.27 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $136.02 | 2021 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kellen Rolling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.